A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Future Oncol
; 18(10): 1175-1183, 2022 Mar.
Article
de En
| MEDLINE
| ID: mdl-35114800
Recent advances in technology have improved the outcomes of stomach cancer patients. However, there are still many patients who die of cancer that has spread from another part of the body. Neoadjuvant intraperitonealsystemic chemotherapy has been acknowledged as a more aggressive treatment for stomach cancer patients with peritoneal metastasis (cancer that has spread to the very thin layer of tissue on the inside of the abdomen that covers the stomach and other organs). In this study, 238 patients will be randomly separated into two groups in a 2:1 ratio after evaluation. The experimental group will receive the proposed neoadjuvant intraperitonealsystemic chemotherapy regimen, whereas the control group will receive a Paclitaxel + S-1 (PS) chemotherapy regimen. The endpoints for the study are how long patients live, number of patients who respond to treatment, number of patients who undergo surgery, how long patients live without their disease getting worse and problems caused by treatment. Trial registration number: ChiCTR-IIR-16009802.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du péritoine
/
Tumeurs de l'estomac
/
Protocoles de polychimiothérapie antinéoplasique
/
Traitement néoadjuvant
Type d'étude:
Clinical_trials
/
Observational_studies
Limites:
Humans
Langue:
En
Journal:
Future Oncol
Année:
2022
Type de document:
Article
Pays d'affiliation:
Chine
Pays de publication:
Royaume-Uni